[Federal Register Volume 89, Number 41 (Thursday, February 29, 2024)]
[Notices]
[Pages 14844-14845]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04197]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Meeting of the CDC/HRSA Advisory Committee on HIV, Viral 
Hepatitis and STD Prevention and Treatment

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC) and the Health 
Resources and Services Administration (HRSA) announce the following 
meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and 
STD Prevention and Treatment (CHAC). This meeting is open to the 
public, limited only by the number of audio and web conference lines 
(1,000 lines are available). Time will be available for public comment 
(registration is required to provide oral comment).

DATES: The meeting will be held on April 9 and 10, 2024, from 9 a.m. to 
4:30 p.m., EDT.
    Written comments must be submitted by April 19, 2024. Registration 
to make oral comments must be submitted by March 26, 2024.

ADDRESSES: The telephone access number is 1-669-254-5252, Webinar ID: 
160 972 1316, and the Passcode is 08044152. The web conference access 
is https://cdc.zoomgov.com/j/1609721316?pwd=cUVqdUp5dlBNaDhhWERrcWdXUk9yUT09, and the Passcode is 
dx%cJGp3. The number of available audio and web conference lines is 
1,000.

FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee 
Management Lead, Office of Policy, Planning, and Partnerships, National 
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6, 
Atlanta, Georgia 30329-4027. Telephone: (404) 639-3423; Email: 
<a href="/cdn-cgi/l/email-protection#056b666d6d767175756a696c667c456661662b626a73"><span class="__cf_email__" data-cfemail="4f212c27273c3b3f3f2023262c360f2c2b2c61282039">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 
    Purpose: The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis 
and STD Prevention and Treatment (CHAC) is charged with advising the 
Secretary of Health and Human Services; the Director, Centers for 
Disease Control and Prevention (CDC); and the Administrator, Health 
Resources and Services Administration (HRSA), regarding objectives, 
strategies, policies, and priorities for HIV, viral hepatitis, and STD 
prevention and treatment efforts including (1) surveillance; (2) 
epidemiologic, behavioral, health services, and laboratory research; 
(3) identification of policy issues and opportunities related to 
prevention and treatment including but not limited to professional 
education, healthcare delivery, social determinants of health, 
research, and prevention and treatment services; (4) strategic issues 
influencing the ability of CDC and HRSA to fulfill their missions; (5) 
development and implementation of federal programs focused on 
prevention and treatment; and (6) provide support to the agencies in 
their response to emerging health needs.
    Matters to be Considered: The agenda will include discussions on 
(1) syndemic approach to testing, (2) using prescription data to 
support the HIV care continuum, (3) HIV and aging, (4) an update on 
DoxyPEP, (5) advancing diagnosis of hepatitis C virus infection, (6) an 
update from the Long-Acting Injectable Workgroup, (7) an update from 
the Community Partnerships Workgroup, (8) an update from the

[[Page 14845]]

Workforce Workgroup, and (9) an update from the Presidential Advisory 
Council on HIV/AIDS. Agenda items are subject to change as priorities 
dictate.

Public Participation

    Written Public Comment: Members of the public are welcome to submit 
written comments in advance of the meeting. Written comments must be 
submitted by emailing <a href="/cdn-cgi/l/email-protection#5d333e35352e292d2d3231343e241d3e393e733a322b"><span class="__cf_email__" data-cfemail="e08e838888939490908f8c898399a0838483ce878f96">[email protected]</span></a> with subject line ``Spring 
CHAC Public Comment Registration'' by April 19, 2024.
    Oral Public Comment: Individuals who would like to make an oral 
comment during the public comment period must register by emailing 
<a href="/cdn-cgi/l/email-protection#ec828f84849f989c9c8380858f95ac8f888fc28b839a"><span class="__cf_email__" data-cfemail="5638353e3e25222626393a3f352f1635323578313920">[email protected]</span></a> with subject line ``Spring CHAC Public Comment 
Registration'' by March 26, 2024. The public comment period is on April 
9, 2024, at 3:45 p.m., EDT.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-04197 Filed 2-28-24; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>